Cargando…
Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Her...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/ https://www.ncbi.nlm.nih.gov/pubmed/33830645 http://dx.doi.org/10.1111/1759-7714.13892 |
_version_ | 1783702032152002560 |
---|---|
author | Watanabe, Kageaki Okuma, Yusuke Kawai, Shoko Nagamata, Makoto Hosomi, Yukio |
author_facet | Watanabe, Kageaki Okuma, Yusuke Kawai, Shoko Nagamata, Makoto Hosomi, Yukio |
author_sort | Watanabe, Kageaki |
collection | PubMed |
description | BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Here, we conducted a phase II trial of this drug in patients with previously treated MPM. METHODS: Eligible patients with MPM having adequate organ function and a performance status of 0–2 were enrolled after disease progression following pemetrexed/platinum therapy. Patients received 35 mg/m(2) AMR on days 1–3 every three weeks until tumor progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Median progression‐free survival (PFS), overall survival (OS), number of treatment cycles, and adverse events were evaluated as secondary endpoints. RESULTS: This trial was discontinued because of low accrual. From September 2013 to July 2018, five patients with MPM were enrolled. Stable disease (SD) was observed in three patients (60%), and progressive disease was noted in two patients (40%). The median PFS was 2.4 (range, 1.2–11.2) months, and the median OS was 9.1 (range, 6.2–22.0) months. The median number of treatment cycles was three (range, 2–11). Grade 1/2 toxicities were observed in all patients. Grade 3/4 neutropenia was observed in four patients (80%), but there were no cases of febrile neutropenia. CONCLUSIONS: Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM. |
format | Online Article Text |
id | pubmed-8169308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-81693082021-06-05 Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma Watanabe, Kageaki Okuma, Yusuke Kawai, Shoko Nagamata, Makoto Hosomi, Yukio Thorac Cancer Original Articles BACKGROUND: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Here, we conducted a phase II trial of this drug in patients with previously treated MPM. METHODS: Eligible patients with MPM having adequate organ function and a performance status of 0–2 were enrolled after disease progression following pemetrexed/platinum therapy. Patients received 35 mg/m(2) AMR on days 1–3 every three weeks until tumor progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Median progression‐free survival (PFS), overall survival (OS), number of treatment cycles, and adverse events were evaluated as secondary endpoints. RESULTS: This trial was discontinued because of low accrual. From September 2013 to July 2018, five patients with MPM were enrolled. Stable disease (SD) was observed in three patients (60%), and progressive disease was noted in two patients (40%). The median PFS was 2.4 (range, 1.2–11.2) months, and the median OS was 9.1 (range, 6.2–22.0) months. The median number of treatment cycles was three (range, 2–11). Grade 1/2 toxicities were observed in all patients. Grade 3/4 neutropenia was observed in four patients (80%), but there were no cases of febrile neutropenia. CONCLUSIONS: Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM. John Wiley & Sons Australia, Ltd 2021-04-08 2021-06 /pmc/articles/PMC8169308/ /pubmed/33830645 http://dx.doi.org/10.1111/1759-7714.13892 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Watanabe, Kageaki Okuma, Yusuke Kawai, Shoko Nagamata, Makoto Hosomi, Yukio Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title | Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title_full | Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title_fullStr | Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title_full_unstemmed | Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title_short | Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
title_sort | premature phase ii study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169308/ https://www.ncbi.nlm.nih.gov/pubmed/33830645 http://dx.doi.org/10.1111/1759-7714.13892 |
work_keys_str_mv | AT watanabekageaki prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma AT okumayusuke prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma AT kawaishoko prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma AT nagamatamakoto prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma AT hosomiyukio prematurephaseiistudyofamrubicinaspalliativechemotherapyforpreviouslytreatedmalignantpleuralmesothelioma |